363 related articles for article (PubMed ID: 27295069)
1. Hsp90: Friends, clients and natural foes.
Verma S; Goyal S; Jamal S; Singh A; Grover A
Biochimie; 2016 Aug; 127():227-40. PubMed ID: 27295069
[TBL] [Abstract][Full Text] [Related]
2. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
3. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
4. The Hsp90 chaperone machinery: from structure to drug development.
Hahn JS
BMB Rep; 2009 Oct; 42(10):623-30. PubMed ID: 19874705
[TBL] [Abstract][Full Text] [Related]
5. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
Hall JA; Seedarala S; Rice N; Kopel L; Halaweish F; Blagg BS
J Nat Prod; 2015 Apr; 78(4):873-9. PubMed ID: 25756299
[TBL] [Abstract][Full Text] [Related]
6. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones.
Prodromou C; Siligardi G; O'Brien R; Woolfson DN; Regan L; Panaretou B; Ladbury JE; Piper PW; Pearl LH
EMBO J; 1999 Feb; 18(3):754-62. PubMed ID: 9927435
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
Blagg BS; Kerr TD
Med Res Rev; 2006 May; 26(3):310-38. PubMed ID: 16385472
[TBL] [Abstract][Full Text] [Related]
9. Cruentaren A binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery.
Hall JA; Kusuma BR; Brandt GE; Blagg BS
ACS Chem Biol; 2014 Apr; 9(4):976-85. PubMed ID: 24450340
[TBL] [Abstract][Full Text] [Related]
10. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications.
Özgür A; Tutar Y
Anticancer Agents Med Chem; 2016; 16(3):280-90. PubMed ID: 26295332
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
12. Functional specificity of co-chaperone interactions with Hsp90 client proteins.
Riggs DL; Cox MB; Cheung-Flynn J; Prapapanich V; Carrigan PE; Smith DF
Crit Rev Biochem Mol Biol; 2004; 39(5-6):279-95. PubMed ID: 15763706
[TBL] [Abstract][Full Text] [Related]
13. Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs.
Phillips JJ; Yao ZP; Zhang W; McLaughlin S; Laue ED; Robinson CV; Jackson SE
J Mol Biol; 2007 Oct; 372(5):1189-203. PubMed ID: 17764690
[TBL] [Abstract][Full Text] [Related]
14. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones.
Li J; Soroka J; Buchner J
Biochim Biophys Acta; 2012 Mar; 1823(3):624-35. PubMed ID: 21951723
[TBL] [Abstract][Full Text] [Related]
15. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32.
Chatterjee BK; Jayaraj A; Kumar V; Blagg B; Davis RE; Jayaram B; Deep S; Chaudhuri TK
J Biol Chem; 2019 Apr; 294(16):6450-6467. PubMed ID: 30792306
[TBL] [Abstract][Full Text] [Related]
17. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins.
McLaughlin SH; Sobott F; Yao ZP; Zhang W; Nielsen PR; Grossmann JG; Laue ED; Robinson CV; Jackson SE
J Mol Biol; 2006 Feb; 356(3):746-58. PubMed ID: 16403413
[TBL] [Abstract][Full Text] [Related]
18. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
Koay YC; Wahyudi H; McAlpine SR
Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Asymmetry in Hsp90 Dimers.
Flynn JM; Mishra P; Bolon DN
J Mol Biol; 2015 Sep; 427(18):2904-11. PubMed ID: 25843003
[TBL] [Abstract][Full Text] [Related]
20. The chaperone Hsp90: changing partners for demanding clients.
Röhl A; Rohrberg J; Buchner J
Trends Biochem Sci; 2013 May; 38(5):253-62. PubMed ID: 23507089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
